IBD

Safety and efficacy of switching to biosimilars in IBD

CT-P13, a biosimilar of infliximab, has just entered the European market, but clinical data are scarce so far. In a recent study, 83 patients with IBD were switched from infliximab to CT-P13 to investigate the safety, efficacy, pharmacokinetic profile and immunogenicity of CT-P13. Median change in disease activity was zero and median levels of C-reactive protein and faecal calprotectin did not change during follow-up. In addition, no serious adverse events were observed. Thus, switching to CT-P13 does not have a negative effect on short-term clinical outcomes.

References

  1. 1

    Smits, L. J. et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J. Crohns Colitis http://dx.doi.org/10.1093/ecco-jcc/jjw087 (2016)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leake, I. Safety and efficacy of switching to biosimilars in IBD. Nat Rev Gastroenterol Hepatol 13, 314 (2016). https://doi.org/10.1038/nrgastro.2016.79

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing